These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 10155610)

  • 1. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.
    Nuijten MJ; Hardens M; Souêtre E
    Pharmacoeconomics; 1995 Aug; 8(2):159-68. PubMed ID: 10155610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study.
    Hosák L; Tůma I; Hanus H; Straka L
    Acta Medica (Hradec Kralove); 2000; 43(4):133-7. PubMed ID: 11294131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic appraisal of citalopram in the management of single-episode depression.
    Sclar DA; Skaer TL; Robison LM; Galin RS
    J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):47S-54S. PubMed ID: 10507508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria.
    Brown MC; Nimmerrichter AA; Guest JF
    Eur Psychiatry; 1999 Jul; 14(4):230-44. PubMed ID: 10572352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the cost effectiveness of antidepressant treatment in primary care.
    Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
    Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomics of antidepressants in moderate-to-severe depressive disorder in Colombia.
    Machado M; Lopera MM; Diaz-Rojas J; Jaramillo LE; Einarson TR;
    Rev Panam Salud Publica; 2008 Oct; 24(4):233-9. PubMed ID: 19133171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of clinical guidelines for continuation treatment in major depression.
    Nuijten MJ
    Value Health; 2001; 4(4):281-94. PubMed ID: 11705296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.
    Armstrong EP; Malone DC; Erder MH
    Curr Med Res Opin; 2008 Apr; 24(4):1115-21. PubMed ID: 18331669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
    Wade AG; Toumi I; Hemels ME
    Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.
    Revicki DA; Brown RE; Keller MB; Gonzales J; Culpepper L; Hales RE
    J Clin Psychiatry; 1997 Feb; 58(2):47-58. PubMed ID: 9062373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
    Wade AG; Toumi I; Hemels ME
    Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
    Armstrong EP; Skrepnek GH; Haim Erder M
    Curr Med Res Opin; 2007 Feb; 23(2):251-8. PubMed ID: 17288678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost analysis of paroxetine versus imipramine in major depression.
    Bentkover JD; Feighner JP
    Pharmacoeconomics; 1995 Sep; 8(3):223-32. PubMed ID: 10155618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When is it worth introducing a quality improvement program? A mathematical model.
    Gandjour A; Lauterbach KW
    Med Decis Making; 2003; 23(6):518-25. PubMed ID: 14672112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial.
    Künzel HE; Ackl N; Hatzinger M; Held K; Holsboer-Trachsler E; Ising M; Kaschka W; Kasper S; Konstantinidis A; Sonntag A; Uhr M; Yassouridis A; Holsboer F; Steiger A
    J Psychiatr Res; 2009 Apr; 43(7):702-10. PubMed ID: 19038406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.